Catalyst Calendar

Mon, Sep 28, 2026

1 updates

6:00 AM

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR Zymeworks to

zymeworks.com

Wed, Sep 23, 2026

1 updates

ZYME

4:01 PM

Zymeworks Completes Acquisition of Theravance Biopharma

Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of

zymeworks.com

Tue, Aug 25, 2026

1 updates

ZYME

10:23 AM

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEA Second FDA approval for zanidatamab in less than two years further validates Zymeworks’

zymeworks.com